<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146391</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-107</org_study_id>
    <nct_id>NCT02146391</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal</brief_title>
  <official_title>AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFECT OF FOOD UPON THE PHARMACOKINETICS OF ANDROXAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, randomized, single-center, single-dose, two-way crossover study&#xD;
      of the PK properties of Androxal in healthy male subjects. Twelve male subjects will each&#xD;
      receive a single dose of Androxal 25 mg in both the fed and fasting state.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>â€¢ Cmax of a single dose of 25 mg of Androxal in male subjects in the fed state and fasted state.</measure>
    <time_frame>24 hour</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Normal Volunteers</condition>
  <arm_group>
    <arm_group_label>Androxal 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androxal 25 mg Capsules</intervention_name>
    <arm_group_label>Androxal 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Speak, read, and understand English or Spanish and is willing and able to provide&#xD;
             written informed consent on an IRB-approved form prior to the initiation of any study&#xD;
             procedures;&#xD;
&#xD;
          2. Male; age 18-60 with a BMI of 25-42 kg/m2 inclusive&#xD;
&#xD;
          3. No significant abnormal findings at the screening physical examination as evaluated by&#xD;
             the Investigator;&#xD;
&#xD;
          4. Normal laboratory values (or abnormal but not clinically significant) at screening as&#xD;
             determined by the Investigator;&#xD;
&#xD;
          5. Subject is willing to remain in the clinic for the screening visit and 2 overnight&#xD;
             treatment visits (approximately 36 hours for the treatment visit)&#xD;
&#xD;
          6. Must be able to swallow gelatin capsules;&#xD;
&#xD;
          7. Must be willing to remain in the clinic for the treatment visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to Clomid;&#xD;
&#xD;
          2. Abnormal screening visit vital signs or clinical laboratory evaluation considered&#xD;
             clinically significant by the Investigator;&#xD;
&#xD;
          3. A hematocrit &gt;54% or a hemoglobin &gt;17 g/dL.&#xD;
&#xD;
          4. Subject with a significant organ abnormality or disease as determined by the&#xD;
             Investigator;&#xD;
&#xD;
          5. Any medical condition that would interfere with the study as determined by the&#xD;
             Investigator;&#xD;
&#xD;
          6. Participation in a clinical trial with investigational medication within 30 days prior&#xD;
             to study medication administration;&#xD;
&#xD;
          7. An acute illness within 5 days of study medication administration;&#xD;
&#xD;
          8. Positive urine drug screen at the screening visit;&#xD;
&#xD;
          9. Known history of HIV and/or Hepatitis B or C&#xD;
&#xD;
         10. Tobacco (nicotine products) use in the 3 months prior to the study;&#xD;
&#xD;
         11. A mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study and/or evidence of an uncooperative attitude, as&#xD;
             determined by the Investigator;&#xD;
&#xD;
         12. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary&#xD;
             embolism);&#xD;
&#xD;
         13. History of myocardial infarction, unstable angina, symptomatic heart failure,&#xD;
             ventricular dysrhythmia, or known history of QTc interval prolongation;&#xD;
&#xD;
         14. An employee or family member of an employee of the study site or the Sponsor;&#xD;
&#xD;
         15. Previous participation in a clinical study of Androxal.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>August 7, 2014</last_update_submitted>
  <last_update_submitted_qc>August 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

